When was Sellas Life Sciences founded?

Sellas Life Sciences was founded in 2006 and raised its 1st funding round 12 years after it was founded.

Where is Sellas Life Sciences located?

Sellas Life Sciences is headquartered in Zug, Switzerland.

How many employees does Sellas Life Sciences have?

As of Aug 31, 2026, the latest employee count at Sellas Life Sciences is 19.

Is Sellas Life Sciences a funded company?

Sellas Life Sciences is a funded company, having raised an undisclosed amount across 2 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on May 02, 2018.

When was the latest funding round of Sellas Life Sciences?

Sellas Life Sciences' latest funding was a $***** Post IPO round on Jul 31, 2020, with participation from 0 investor.

What is the annual revenue of Sellas Life Sciences?

Annual revenue of Sellas Life Sciences is between $1M and $10M as on Dec 31, 2022

Where does Sellas Life Sciences rank among its competitors?

Sellas Life Sciences ranks 876th amongst 3382 active competitors, of which 1133 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Sellas Life Sciences?

Sellas Life Sciences' top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Sellas Life Sciences - 2026 Company Profile, Funding, Competitors & Financials

Sellas Life Sciences is a public company based in Zug (Switzerland), founded in 2006. It operates as a Developer of therapeutics for the treatment of cancer. Sellas Life Sciences has raised an undisclosed amount in funding. The company has 3382 active competitors, including 1133 funded and 790 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Developer of therapeutics for the treatment of cancer. The company is focused on the development of novel therapeutics for a broad range of cancer indications which include galinpepimut-S a cancer immunotherapeutic agent that targets the Wilms tumor 1 and SLS009, a highly selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

Key Metrics

Founded Year

2006

Location

Zug, Switzerland

Stage

Public

Latest Funding Round

Post IPO, Jul 31, 2020, $*****

Ranked

876^th among 3382 active competitors

Annual Revenue

$1M - $10M as on Dec 31, 2022

Employee Count

19 as on Aug 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3076 more

Exit Details

Public

View Sellas Life Sciences' full profile

Sellas Life Sciences is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
SELLAS LIFE SCIENCES GROUP, INC. CIN: 4398638 , United States, Active	May 06, 2013	-	-	-
SELLAS LIFE SCIENCES GROUP, INC. CIN: 1390478 , United States, Active	Apr 02, 2006	$1M - $10M (As on Dec 31, 2022)	-	-

Sellas Life Sciences got listed on Jun 21, 2017.

Click here to take a look at Sellas Life Sciences's IPO in detail

Sellas Life Sciences has raised funding over 2 rounds. Its first funding round was on May 02, 2018.

Here is the list of recent funding rounds of Sellas Life Sciences:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 31, 2020	4964033	Post IPO	6797535	9235100	7315993	3293990
May 02, 2018	8717983	Post IPO	5909134	7833892	1450545	4068007

Access funding benchmarks and valuations. Sign up today!

View details of Sellas Life Sciences's funding rounds and investors

Sellas Life Sciences' employee count trend

Sellas Life Sciences has 19 employees as of Aug 26. Here is Sellas Life Sciences's employee count trend over the years:

Employee count trend for Sellas Life Sciences

Uncover Sellas Life Sciences' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Sellas Life Sciences include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Sellas Life Sciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
876th	Sellas Life Sciences 2006, Zug (Switzerland), Public	Developer of therapeutics for the treatment of cancer	-	-	44/100